Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.46 |
| ▸ | MTOR | P42345 | 5/20 | 0.46 |
| ▸ | AKT1 | P31749 | 4/20 | 0.46 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | LGMN | Q99538 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16807343 | 0.84 | ALDH1A1 (0.41) | PIK3CAMTORAKT1AGXTKDM4E | |
| SCHEMBL5130191 | 0.82 | NCF1 (0.46) | PIK3CAAGXTLGMNMAPTSMN1; SMN2 | |
| SCHEMBL1172028 | 0.82 | LGMN (0.53) | PIK3CAMTORAGXTLGMNKDM4E | |
| SCHEMBL2712064 | 0.82 | LGMN (0.53) | PIK3CAMTORAGXTLGMNKDM4E | |
| SCHEMBL12865160 | 0.80 | LMNA (0.53) | PIK3CAMTORAKT1AGXTKDM4E | |
| SCHEMBL1662765 | 0.80 | GPR183 (0.45) | PIK3CAMTORAKT1AGXTKDM4E | |
| SCHEMBL4436536 | 0.80 | AGXT (0.48) | PIK3CAMTORAKT1AGXTLGMN | |
| SCHEMBL5129937 | 0.80 | HRH3 (0.46) | PIK3CAAGXTLGMNMAPTALDH1A1 | |
| SCHEMBL7537112 | 0.78 | CHKA (0.49) | PIK3CAMTORAKT1LGMNKDM4E | |
| SCHEMBL5129082 | 0.77 | ALDH1A1 (0.43) | PIK3CAMTORAKT1AGXTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609836-B2 | 4-aryl-2-anilino-pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-17 | — | — | US | disclosed |
| EP-2283024-B1 | 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-15 | — | — | EP | disclosed |
| US-20130053379-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-28 | — | — | US | disclosed |
| US-8318929-B2 | 4-aryl-2-anilino-pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| EP-2283024-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2011-02-16 | — | — | EP | disclosed |
| US-20110009404-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-13 | — | — | US | disclosed |
| WO-2009112439-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-17 | — | — | WO | disclosed |
| EP-1981856-A2 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008104754-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2007085833-A2 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | EPHB4, EPHB1, NME2 | PIK3CA 203/4885MTOR 1171/4885AKT1 496/4885 |
| US-20130053379-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | PLK4, PLK3, PLK2 | PIK3CA 53/4885MTOR 1341/4885AKT1 439/4885 |
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | EPHB4, EPHB1, EPHB3 | PIK3CA 176/4885MTOR 1307/4885AKT1 220/4885 |
| US-20110009404-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | PLK4, PLK3, PLK2 | PIK3CA 53/4885MTOR 1341/4885AKT1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.